Karolinska Development’s portfolio company PharmNovo receives approval to initiate a phase 2a trial of its drug candidate PN6047 in Spain
Karolinska Development’s portfolio company PharmNovo receives approval to initiate a phase 2a trial of its drug candidate PN6047 in Spain